Dr Stephen Wong
Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology
31 Scholarly works
1 Projects
HIGHLIGHTS
2025
Journal article
Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials.
DOI: 10.1200/PO-25-002452025
Journal article
Lung cancer biobanking in Australia: challenges and future directions
DOI: 10.5694/mja2.700122024
Journal article
Unravelling mutational signatures with plasma circulating tumour DNA
DOI: 10.1038/s41467-024-54193-22024
Journal article
Plasma ctDNA enables early detection of temozolomide resistance mutations in glioma
DOI: 10.1093/noajnl/vdae0412021
Research grants (ARC, NHMRC, MRFF)
Defining the Plasma Methylome to Guide Melanoma Treatment.
2019
Journal article
Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
DOI: 10.1038/s41591-018-0243-z2013
Journal article
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage
DOI: 10.1158/1078-0432.CCR-13-0398
RECENT SCHOLARLY WORKS
2024
Journal article
Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma
DOI: 10.1093/noajnl/vdae0272023
Journal article
The landscape of cell-free mitochondrial DNA in liquid biopsy for cancer detection
DOI: 10.1186/s13059-023-03074-w2022
Journal article
Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma
DOI: 10.1097/SLA.00000000000051772022
Conference Proceedings
DETECTION phase II/III trial: Circulating tumor DNA-guided therapy for stage IIB/C melanoma after surgical resection.
DOI: 10.1200/jco.2022.40.16_suppl.tps96032021
Conference Proceedings
Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE)
DOI: 10.1016/j.jtho.2021.01.11212019
Journal article
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
DOI: 10.1016/j.ccell.2019.08.008